These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 1988143

  • 1. Development and characterization of a melphalan-resistant human multiple myeloma cell line.
    Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM.
    Cancer Res; 1991 Feb 01; 51(3):995-1002. PubMed ID: 1988143
    [Abstract] [Full Text] [Related]

  • 2. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.
    Green JA, Vistica DT, Young RC, Hamilton TC, Rogan AM, Ozols RF.
    Cancer Res; 1984 Nov 01; 44(11):5427-31. PubMed ID: 6488194
    [Abstract] [Full Text] [Related]

  • 3. Effect of D,L-buthionine-S,R-sulfoximine on cytotoxicity and DNA cross-linking induced by bifunctional DNA-reactive cytostatic drugs in human melanoma cells.
    Hansson J, Edgren M, Ehrsson H, Ringborg U, Nilsson B.
    Cancer Res; 1988 Jan 01; 48(1):19-26. PubMed ID: 3334994
    [Abstract] [Full Text] [Related]

  • 4. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
    Wang YY, Teicher BA, Shea TC, Holden SA, Rosbe KW, al-Achi A, Henner WD.
    Cancer Res; 1989 Nov 15; 49(22):6185-92. PubMed ID: 2804968
    [Abstract] [Full Text] [Related]

  • 5. Alkylator resistance in human B lymphoid cell lines: (1). Melphalan accumulation, cytotoxicity, interstrand-DNA-crosslinks, cell cycle analysis, and glutathione content in the melphalan-sensitive B-lymphocytic cell line (WIL2) and in the melphalan-resistant B-CLL cell line (WSU-CLL).
    Pu Q, Bianchi P, Bezwoda WR.
    Anticancer Res; 2000 Nov 15; 20(4):2561-8. PubMed ID: 10953327
    [Abstract] [Full Text] [Related]

  • 6. Changes in glutathione content and resistance to anticancer agents in human stomach cancer cells induced by treatments with melphalan in vitro.
    Barranco SC, Townsend CM, Weintraub B, Beasley EG, MacLean KK, Shaeffer J, Liu NH, Schellenberg K.
    Cancer Res; 1990 Jun 15; 50(12):3614-8. PubMed ID: 2340510
    [Abstract] [Full Text] [Related]

  • 7. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine.
    Louie KG, Behrens BC, Kinsella TJ, Hamilton TC, Grotzinger KR, McKoy WM, Winker MA, Ozols RF.
    Cancer Res; 1985 May 15; 45(5):2110-5. PubMed ID: 3986765
    [Abstract] [Full Text] [Related]

  • 8. Isolation and characterization of a Chinese hamster ovary cell line resistant to bifunctional nitrogen mustards.
    Robson CN, Alexander J, Harris AL, Hickson ID.
    Cancer Res; 1986 Dec 15; 46(12 Pt 1):6290-4. PubMed ID: 3779647
    [Abstract] [Full Text] [Related]

  • 9. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
    Lai SL, Hwang J, Perng RP, Whang-Peng J.
    Oncol Res; 1995 Dec 15; 7(1):31-8. PubMed ID: 7549042
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Radiation resistance in a melphalan-resistant subline of a rat mammary carcinoma.
    Lehnert S, Vestergaard J, Batist G, Aloui-Jamali MA.
    Radiat Res; 1994 Aug 15; 139(2):232-9. PubMed ID: 8052700
    [Abstract] [Full Text] [Related]

  • 13. Flow cytometric analysis of DNA damage and repair in the cells resistant to alkylating agents.
    Frankfurt OS, Seckinger D, Sugarbaker EV.
    Cancer Res; 1990 Aug 01; 50(15):4453-7. PubMed ID: 2369722
    [Abstract] [Full Text] [Related]

  • 14. Direct relation of DNA lesions in multidrug-resistant human myeloma cells to intracellular doxorubicin concentration.
    Bellamy WT, Dorr RT, Dalton WS, Alberts DS.
    Cancer Res; 1988 Nov 15; 48(22):6360-4. PubMed ID: 3180055
    [Abstract] [Full Text] [Related]

  • 15. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
    Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF, Hamilton TC.
    Cancer Res; 1993 Nov 01; 53(21):5225-32. PubMed ID: 8106143
    [Abstract] [Full Text] [Related]

  • 16. Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage.
    Bellamy WT, Dalton WS, Kailey JM, Gleason MC, McCloskey TM, Dorr RT, Alberts DS.
    Cancer Res; 1988 Nov 15; 48(22):6365-70. PubMed ID: 3180056
    [Abstract] [Full Text] [Related]

  • 17. Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferase activity.
    Alaoui-Jamali MA, Panasci L, Centurioni GM, Schecter R, Lehnert S, Batist G.
    Cancer Chemother Pharmacol; 1992 Nov 15; 30(5):341-7. PubMed ID: 1505071
    [Abstract] [Full Text] [Related]

  • 18. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
    Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, Saporta S, Boulware D, Moscinski L, Alsina M, Dalton WS.
    Cancer Res; 2003 Nov 15; 63(22):7900-6. PubMed ID: 14633719
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.